If asking questions related to timing of value inflection points is negative, yes. If RHY was forthcoming with information, we would not be asking questions.
What their approach is to FDA approvals and China approvals? When does RHY (not shareholders) expect approval by? How they will launch the test in those countries?
These aren't negative. The technology looks incredibly promising. These questions help us all estimate RHY's value and make informed investing decisions.
Ann: Rhythm Extends ColoSTAT Clinical Trial to Western Australia, page-32
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.34M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 11.0¢ | $2.291K | 20.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 23335 | 3 |
View Market Depth
| Last trade - 11.54am 08/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |